Sterility:Article Title: A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants
Article Snippet: Lactobacillus acidophilus , Lactobacillus bulgaricus , Bifidobacterium bifidum (3) , Fructo-oligosaccharide. , Each capsule had 500 mg blend: Lactobacillus acidophilus 2 billion CFU a ; Lactobacillus bulgaricus 1 billion CFU; Bifidobacterium bifidum 1 billion CFU; and fructo-oligosaccharide 100 mg. A total of 0.5 mL (3 × 10 9 CFU) once daily. Mother’s milk. , Started from first feeding by dropper or tube until discharged. , Sample size: n = 119 (probiotics: n = 59; placebo: n = 60) GA ≤ 35 completed weeks BW ≤ 2000 g , Bangladesh , NEC and mortality: Significantly lower NEC incidence (1.7% vs. 13.3%) and mortality compared to the placebo group. , [ ] . .. Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), Streptococcus thermophilus (TH-4 ® ) (3) (Similac ® Probiotic Triblend) (Abbott, Abbott Park, IL, USA; manufactured by Chr. Hansen, HØrsholm, Denmark) , Not available , One billion CFU of Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), and Streptococcus thermophilus (TH-4 ® ) mixed in 3 mL of sterile water. Once daily. All infants started on human milk; 50% of infants discharged on mother’s milk. , First dose of probiotic administered. within 48 h of birth and after first feed of mother’s colostrum (or donor breast milk if colostrum was not available). Probiotic ceased when infant reached 35 weeks postmenstrual age or was discharged. , Sample size: n = (probiotics: n = 125; no probiotics: n = 126) GA < 32 weeks BW < 1500 g , USA , NEC, LOS (late-onset sepsis), and mortality: Decreased incidence of NEC from 6.3% (no probiotic) to 1.6% (probiotic group), but the differences in NEC, LOS, and death were not significant after adjusting for multiple variables. No adverse effects. , [ ] . .. Bifidobacterium infantis (BB–02), Streptococcus thermophilus (TH–4), Bifidobacterium lactis (BB-12) (3) (ABC Dophilus Probiotic Powder for Infants, Solgar ® , Leonia, NJ, USA) , Not available , Bifidobacterium infantis (BB–02 300 × 10 6 ), Streptococcus thermophilus (TH–4 350 × 10 6 ), and Bifidobacterium lactis (BB-12 350 × 10 6 ) with 1 × 10 9 total organisms per 1.5 g in a maltodextrin base powder. Administered daily by reconstituting with breast milk or formula. , Given only when an infant received at least 1 mL of milk every 4 h. The intervention was withheld during periods when infants were nil orally until discharged from hospital or reached corrected age. , Sample size: n = 1099 (probiotics: n = 548; placebo: n = 551) GA < 32 weeks BW < 1500 g , Australia and New Zealand , NEC: Reduced NEC of Bell’s stage II or more significantly (2.0% versus 4.4%). LOS and mortality: No significant difference in definite LOS or all-cause mortality. , [ ] .
Milk:Article Title: A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants
Article Snippet: Lactobacillus acidophilus , Lactobacillus bulgaricus , Bifidobacterium bifidum (3) , Fructo-oligosaccharide. , Each capsule had 500 mg blend: Lactobacillus acidophilus 2 billion CFU a ; Lactobacillus bulgaricus 1 billion CFU; Bifidobacterium bifidum 1 billion CFU; and fructo-oligosaccharide 100 mg. A total of 0.5 mL (3 × 10 9 CFU) once daily. Mother’s milk. , Started from first feeding by dropper or tube until discharged. , Sample size: n = 119 (probiotics: n = 59; placebo: n = 60) GA ≤ 35 completed weeks BW ≤ 2000 g , Bangladesh , NEC and mortality: Significantly lower NEC incidence (1.7% vs. 13.3%) and mortality compared to the placebo group. , [ ] . .. Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), Streptococcus thermophilus (TH-4 ® ) (3) (Similac ® Probiotic Triblend) (Abbott, Abbott Park, IL, USA; manufactured by Chr. Hansen, HØrsholm, Denmark) , Not available , One billion CFU of Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), and Streptococcus thermophilus (TH-4 ® ) mixed in 3 mL of sterile water. Once daily. All infants started on human milk; 50% of infants discharged on mother’s milk. , First dose of probiotic administered. within 48 h of birth and after first feed of mother’s colostrum (or donor breast milk if colostrum was not available). Probiotic ceased when infant reached 35 weeks postmenstrual age or was discharged. , Sample size: n = (probiotics: n = 125; no probiotics: n = 126) GA < 32 weeks BW < 1500 g , USA , NEC, LOS (late-onset sepsis), and mortality: Decreased incidence of NEC from 6.3% (no probiotic) to 1.6% (probiotic group), but the differences in NEC, LOS, and death were not significant after adjusting for multiple variables. No adverse effects. , [ ] . .. Bifidobacterium infantis (BB–02), Streptococcus thermophilus (TH–4), Bifidobacterium lactis (BB-12) (3) (ABC Dophilus Probiotic Powder for Infants, Solgar ® , Leonia, NJ, USA) , Not available , Bifidobacterium infantis (BB–02 300 × 10 6 ), Streptococcus thermophilus (TH–4 350 × 10 6 ), and Bifidobacterium lactis (BB-12 350 × 10 6 ) with 1 × 10 9 total organisms per 1.5 g in a maltodextrin base powder. Administered daily by reconstituting with breast milk or formula. , Given only when an infant received at least 1 mL of milk every 4 h. The intervention was withheld during periods when infants were nil orally until discharged from hospital or reached corrected age. , Sample size: n = 1099 (probiotics: n = 548; placebo: n = 551) GA < 32 weeks BW < 1500 g , Australia and New Zealand , NEC: Reduced NEC of Bell’s stage II or more significantly (2.0% versus 4.4%). LOS and mortality: No significant difference in definite LOS or all-cause mortality. , [ ] .
Probiotics:Article Title: A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants
Article Snippet: Lactobacillus acidophilus , Lactobacillus bulgaricus , Bifidobacterium bifidum (3) , Fructo-oligosaccharide. , Each capsule had 500 mg blend: Lactobacillus acidophilus 2 billion CFU a ; Lactobacillus bulgaricus 1 billion CFU; Bifidobacterium bifidum 1 billion CFU; and fructo-oligosaccharide 100 mg. A total of 0.5 mL (3 × 10 9 CFU) once daily. Mother’s milk. , Started from first feeding by dropper or tube until discharged. , Sample size: n = 119 (probiotics: n = 59; placebo: n = 60) GA ≤ 35 completed weeks BW ≤ 2000 g , Bangladesh , NEC and mortality: Significantly lower NEC incidence (1.7% vs. 13.3%) and mortality compared to the placebo group. , [ ] . .. Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), Streptococcus thermophilus (TH-4 ® ) (3) (Similac ® Probiotic Triblend) (Abbott, Abbott Park, IL, USA; manufactured by Chr. Hansen, HØrsholm, Denmark) , Not available , One billion CFU of Bifidobacterium lactis (BB-12 ® ), Bifidobacterium infantis (BB-02TM), and Streptococcus thermophilus (TH-4 ® ) mixed in 3 mL of sterile water. Once daily. All infants started on human milk; 50% of infants discharged on mother’s milk. , First dose of probiotic administered. within 48 h of birth and after first feed of mother’s colostrum (or donor breast milk if colostrum was not available). Probiotic ceased when infant reached 35 weeks postmenstrual age or was discharged. , Sample size: n = (probiotics: n = 125; no probiotics: n = 126) GA < 32 weeks BW < 1500 g , USA , NEC, LOS (late-onset sepsis), and mortality: Decreased incidence of NEC from 6.3% (no probiotic) to 1.6% (probiotic group), but the differences in NEC, LOS, and death were not significant after adjusting for multiple variables. No adverse effects. , [ ] . .. Bifidobacterium infantis (BB–02), Streptococcus thermophilus (TH–4), Bifidobacterium lactis (BB-12) (3) (ABC Dophilus Probiotic Powder for Infants, Solgar ® , Leonia, NJ, USA) , Not available , Bifidobacterium infantis (BB–02 300 × 10 6 ), Streptococcus thermophilus (TH–4 350 × 10 6 ), and Bifidobacterium lactis (BB-12 350 × 10 6 ) with 1 × 10 9 total organisms per 1.5 g in a maltodextrin base powder. Administered daily by reconstituting with breast milk or formula. , Given only when an infant received at least 1 mL of milk every 4 h. The intervention was withheld during periods when infants were nil orally until discharged from hospital or reached corrected age. , Sample size: n = 1099 (probiotics: n = 548; placebo: n = 551) GA < 32 weeks BW < 1500 g , Australia and New Zealand , NEC: Reduced NEC of Bell’s stage II or more significantly (2.0% versus 4.4%). LOS and mortality: No significant difference in definite LOS or all-cause mortality. , [ ] .
|
![Biplot graph of hedonic [a] and QDA [b] results of probiotic ice cream samples. A: Control ice cream; B: Ice cream containing Bifidobacterium animalis subsp. lactis ; C: Ice cream containing Lactobacillus gasseri ; D: Ice cream containing Bifidobacterium animalis subsp. lactis + Lactobacillus gasseri .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5827/pmc13265827/pmc13265827__FSN3-14-e72030-g002.jpg)
